Clene

Clene ROIC

The Return on Invested Capital (ROIC) of Clene (CLNN) as of Oct 16, 2026 is -641.34 %. In the previous year, Return on Invested Capital (ROIC) was -328.72 % — a change of 95.10% (lower).

ROIC

-641.34 %

YoY

95.10%

Last updated:

Return on Invested Capital (ROIC) of Clene is 2025 -641.34 % . Return on Invested Capital (ROIC) of Clene was 2024 -328.72 % . It decreases by 95.10% lower compared to the previous year.

The Clene ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
-3.37 USD
Jan 1, 2019
-208.02 USD
Jan 1, 2020
-413.31 USD
Jan 1, 2021
-26.58 USD
Jan 1, 2022
-85.33 USD
Jan 1, 2023
-108.68 USD
Jan 1, 2024
-328.72 USD
Jan 1, 2025
-641.34 USD
The Clene ROIC history
YEARROICYoY
-641.34 %+95.10%
-328.72 %+202.47%
-108.68 %+27.36%
-85.33 %+220.99%
-26.58 %-93.57%
-413.31 %+98.69%
-208.02 %+6,069.15%
-3.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, operating within the health care sector and specifically in the biotechnology industry. The company went public via an IPO on August 27, 2018, and currently employs 75 full-time staff. Clene focuses on developing therapeutics for neurodegenerative diseases, with its primary drug candidate being CNM-Au8, an oral suspension of gold nanocrystals. The company's research targets energetic failure, an underlying factor in many neurological conditions, aiming to restore neuronal health and function by enhancing energy production and utilization. CNM-Au8 works through catalytically active nanocrystals that support cellular energy processes, promoting neuroprotection and remyelination by improving resilience to disease-related stressors. The company also has other product candidates, including CNM-ZnAg, a spectrum antiviral and antibacterial agent composed of zinc and silver ions, and CNM-AgZn17, a gel polymer suspension of zinc and silver designed for treating infectious diseases and supporting wound healing. Clene's website is https://clene.com/ and it is listed under the ticker CLNN with ISIN US1856342019. The company remains in the clinical development phase, focusing on advancing its pipeline of treatments for neurological and infectious conditions. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Return on Invested Capital (ROIC) of Clene is -641.34 % in 2025.

Return on Invested Capital (ROIC) of Clene changed from -328.72 % to -641.34 %, representing a 95.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Clene since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Clene with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Clene

All Key Metrics — Clene